This section of the website is for UK healthcare professionals only. If you are not a healthcare professional, please click here.
This section of the website is for UK healthcare professionals only. If you are not a healthcare professional, please click here.

About PREVYMIS®▼ (letermovir)

Prescribing Information

A prophylactic option for CMV reactivation in adult R+ allogeneic HSCT recipients

PREVYMIS (letermovir) is the first and only CMV terminase inhibitor indicated for prophylaxis of cytomegalovirus (CMV) reactivation and disease in adult CMV-seropositive recipients [R+] of an allogeneic haematopoietic stem cell transplant (HSCT).1

With its novel mechanism of action, PREVMYIS targets a component of the terminase complex involved in viral DNA cleavage and packaging.1 Cross-resistance is therefore not likely with agents with a different mechanism of action.1

CMV is associated with an increased risk of overall mortality in the first year post-HSCT, independent of pre-emptive therapy use2

In a phase III clinical trial, PREVYMIS demonstrated –

  • Superior efficacy in CMV prophylaxis at week 24 compared to placebo1
  • Lower all-cause mortality vs placebo at week 24 post-transplant3*
  • A generally well tolerated safety profile1
  • Once-daily oral dosing – as early as day 0 and through day 100 post-transplant1

Start PREVYMIS as early as day 0 post-transplant in adult CMV-seropositive (R+) allogeneic HSCT patients1

(Not an actual patient.) *Based on a pre-specified exploratory endpoint

What impact could prophylaxis with PREVYMIS (letermovir) have for your patients?

Prescribing Information

Length: 08:41

Professor Karl Peggs, Professor of Transplant Science and Cancer Immunotherapy, UCL Cancer Institute.

PREVYMIS is indicated for prophylaxis of cytomegalovirus (CMV) reactivation and disease in adult CMV-seropositive recipients [R+] of an allogeneic haematopoietic stem cell transplant (HSCT).1 Here, Professor Peggs introduces letermovir and discusses the trial data including its mechanism of action, efficacy, safety and toxicity profile. The introduction of this form of prophylaxis and its potential implications for clinical practice is also discussed.

Related content

 

References

  1. PREVYMIS Summary of Product Characteristics.
  2. Green ML, Leisenring W, Xie H, et al. Cytomegalovirus viral load and mortality after haematopoietic stem cell transplantation in the era of pre-emptive therapy: a retrospective cohort study. Lancet Haematol. 2016;3:e119-e127.
  3. Marty FM, Ljungman P, Chemaly RF, et al. Letermovir prophylaxis for cytomegalovirus in hematopoietic-cell transplantation. N Engl J Med. 2017;377:2433–2444.

Supporting documentation

Prescribing Information | Summary of Product Characteristics | Patient Information Leaflet

GB-CYT-00236 | Date of Preparation: January 2021